Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) 是有机阴离子转运多肽 1B(OATP1B) 和 OATP1B3抑制剂,IC50分别为 1.5 µM 和 3.27 µM。它也具有口服活性的 HCV NS5A 蛋白抑制剂,多种 HCV 复制子基因型的 EC50范围为 9-146 pM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 279 | 现货 | ||
10 mg | ¥ 393 | 现货 | ||
50 mg | ¥ 543 | 现货 | ||
100 mg | ¥ 663 | 现货 | ||
500 mg | ¥ 1,650 | 现货 | ||
1 g | ¥ 2,450 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 418 | 现货 |
产品描述 | Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) and is used in combination with other oral antiviral agents to treat chronic hepatitis C. Elevations in serum enzyme levels during daclatasvir therapy are uncommon, and it has yet to be convincingly implicated in cases of clinically apparent liver injury with jaundice. |
靶点活性 | HCV replicon genotype 1a:50 pM (EC50), HCV replicon genotype 3a:146 pM (EC50), NS5A26-202:210 nM (Kd), HCV replicon genotype 5a:33 pM (EC50), NS5A33-202:8 nM (Kd), HCV replicon genotype 4a:12 pM (EC50), OATP1B3:3.27 µM (IC50), HCV replicon genotype 2a:71 pM (EC50), HCV replicon genotype 1b:9 pM (EC50), OATP1B:1.5 µM (IC50) |
激酶实验 | CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792-928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and Palbociclib (0.001-0.1 μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25°C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4°C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter. |
别名 | BMS-790052 dihydrochloride, 盐酸达拉他韦 |
分子量 | 811.8 |
分子式 | C40H52Cl2N8O6 |
CAS No. | 1009119-65-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (67.75 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.2318 mL | 6.1592 mL | 12.3183 mL | 30.7958 mL |
5 mM | 0.2464 mL | 1.2318 mL | 2.4637 mL | 6.1592 mL | |
10 mM | 0.1232 mL | 0.6159 mL | 1.2318 mL | 3.0796 mL | |
20 mM | 0.0616 mL | 0.308 mL | 0.6159 mL | 1.5398 mL | |
50 mM | 0.0246 mL | 0.1232 mL | 0.2464 mL | 0.6159 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Daclatasvir dihydrochloride 1009119-65-6 Microbiology/Virology Proteases/Proteasome HCV Protease EBP-883 BMS 790052 genotypes Inhibitor BMS790052 inhibit JFH-1 Daclatasvir BMS790052 Dihydrochloride OATP1B3 antiviral NS5A Hepatitis C virus OATP1B1 BMS-790052 dihydrochloride replicon BMS-790052 EBP883 BMS 790052 Dihydrochloride Daclatasvir Dihydrochloride HCV 盐酸达拉他韦 EBP 883 BMS-790052 Dihydrochloride inhibitor